NOT.F - Novartis AG

Frankfurt - Frankfurt Delayed price. Currency in EUR
80.16
0.00 (0.00%)
At close: 07:57PM CEST
Stock chart is not supported by your current browser
Previous close80.16
Open0.00
Bid80.11 x 30000
Ask80.34 x 30000
Day's range0.00 - 0.00
52-week range
Volume1,589
Avg. volume0
Market cap179.196B
Beta (5Y monthly)N/A
PE ratio (TTM)8.30
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA

    Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2 Sandoz continues to build its biosimilars portfolio to increase patient access to high-

  • Globe Newswire

    New Sandoz Board of Directors appointed

    Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2 2023 Experienced and diverse group of corporate leaders with a track record of growing businesses and driving value for the organization and society will help set strategic direction for Sandoz and support its future development Basel, May 15, 2023 — Sandoz takes the next steps to prepare for the pl

  • Globe Newswire

    Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

    Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III ASCEMBL trial reaffirm Scemblix superiority over Bosulif* in patients with chronic myeloid leukemia (CML) in chronic phase, previously treated with two or more tyrosine kinase inhibitors Preliminary global results from large-scale Survey on Unmet Needs in CML disrupt notion that CML is solved and underscore import

  • Globe Newswire

    Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

    Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform that delivers fully integrated drug substance development and continuous manufacturing Partnership supports Sandoz pipeline expansion to 24 biosimilar assets, provides opportunity to enhance integrated development and manufacturing network Basel, May 9, 2023 — Sandoz, a global leader in off-patent (ge

  • Globe Newswire

    Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

    Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six anticipated to be first-to-market Sandoz continues to expand patient access to much-needed medications, drive patient savings, and ensure the sustainability of healthcare systems worldwide Basel, May 4, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that it has sig

  • Globe Newswire

    Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

    Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase III data showing Cosentyx® (secukinumab) provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1–4 Safety findings were consistent with the known safety profile of Cosentyx across its five approved indications1 Regulatory decision from the US Food and

  • Globe Newswire

    Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

    Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of recurrence, including those with no nodal involvement, to be presentedNew analyses from the Pluvicto VISION trial in prostate cancer and the JDQ443 KontRASt-01 trial in KRAS G12C-mutated lung cancer among 40+ Novartis abstracts accepted at ASCO, underscoring strength of Novartis oncology portfolio and thera

  • Globe Newswire

    Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

    Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline without the need for blood transfusions1 Secondary endpoints show clinically meaningful benefits, including achieving 12 g/dL or more hemoglobin levels and blood-transfusion independence in the vast majority of patients, no cases of clinical breakthrough hemolysis, reduction of lactate dehy

  • Globe Newswire

    Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

    Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating income +18% (cc, +11% USD)IM core margin 38.7%, +360 bps cc, driven by higher sales and productivity programsGrowth driven by strong performance of Entresto, Pluvicto, Kesimpta, Kisqali and ScemblixSandoz sales grew +8% (cc, +4% USD) and core operating income +3% (cc, -2% USD) Operating income grew

  • Globe Newswire

    Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

    The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of disability progression versus those who switched later from teriflunomide to Kesimpta1Outcomes related to both disability progression and brain volume change up to five years favored earlier initiation of Kesimpta in people living with RMS1A separate ALITHIOS analysis showed consistent safety profil

  • Globe Newswire

    Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

    Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers patients enhanced yet familiar experience through increased convenience and reduced injection volumeApproval further solidifies expansion of Sandoz biosimilar immunology portfolio in Europe Basel, April 3, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announc

  • Globe Newswire

    Novartis Entresto receives positive CHMP opinion for pediatric heart failure

    If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric heart failure is an important cause of childhood morbidity and mortality – up to a third of all pediatric cardiac admissions are due to heart failure; these hospitalizations are associated with a 20-fold increase in the risk of death1,2 The positive opinion is based on final data from the 52-week Phase I

  • Globe Newswire

    Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

    Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III study of a CDK4/6 inhibitor demonstrating consistent benefit in a broad population of patients with stage II and III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with no nodal involvementApproximately 30-60% of people with HR+/HER2- s

  • Globe Newswire

    Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulationSandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimil

  • Globe Newswire

    Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

    Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walkingTo date, more than 3,000 children with spinal muscular atrophy have been treated with Zolgensma across clinical trials, managed access programs and in the commercial setting1 Additionally, children wi

  • Globe Newswire

    Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

    New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months mPFS for standard of care1,2 Approval also received for liquid formulation options for ease of administration across multiple approved indicationsTafinlar + Mekinist is now approved in six indications across multiple BRAF V600E solid tumors, including melanoma, thyroid cancer and lung cancer1,2 Basel,

  • Globe Newswire

    Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines

    Sandoz investment expected to be at least USD 400m – MOU signed today in Ljubljana at ceremony led by Slovenian Prime Minister and Sandoz CEO New project underpins Sandoz ambition to drive future growth of biosimilars, addressing increasing global demand One of largest-ever international private-sector investments in Slovenia, reinforces extensive Europe-wide Sandoz production network Basel, March 9, 2023 – Sandoz, a global leader in generic and biosimilar medicines, today signed a Memorandum of

  • Globe Newswire

    Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

    Shareholders approve 26th consecutive dividend increase to CHF 3.20 (+3.2%) per share for 2022; representing a 4.0% yield1 and approximately 61% payout of free cash flow Shareholders confirm Joerg Reinhardt as Chair of the Board of Directors as well as all other members who stood for re-election; John D. Young newly elected to the Board of Directors Shareholders approve all other proposals of the Board of Directors, including the amendment of the Articles of Incorporation, the 2022 Compensation

  • Globe Newswire

    Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

    Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin role as Sandoz Chairman following the spin-off from Novartis Basel, February 20, 2022 — Novartis Board of Directors announced today the appointment of Gilbert Ghostine as Chairman-designate of the new Board of Directors of Sandoz. Mr. Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste c

  • Globe Newswire

    Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA

    Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2 Sandoz continues to build biosimilars portfolio to increase patient access to high-quality therapies and support healthcare system sustainability Basel, February 06, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US Food and Drug Administration (FDA) has accept

  • Globe Newswire

    Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

    In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a

  • Globe Newswire

    Novartis continues to grow with further core margin expansion and achieves important innovation milestones

    Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income +8% (cc, 0% USD), with IM core margin reaching 36.9% (+130 bps cc)Sandoz sales grew +4% (cc, -4% USD) with core operating income decreasing -1% (cc, -8% USD) Operating income declined -13% (cc, -21% USD), mainly due to higher restructuring and impairments. Net income declined -67% (cc, -71% USD), or -9

  • Globe Newswire

    Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar

    Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar experience through increased convenience and reduced injection volumeRecommendation further supports expansion of Sandoz biosimilar immunology portfolio in Europe Basel, January 30, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee fo

  • Globe Newswire

    Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

    Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolioAddition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar)

  • Globe Newswire

    Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

    Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH) patients with residual anemia despite prior anti-C5 therapy1 Iptacopan demonstrated an 80% difference to anti-C5 in the estimated proportion of patients* achieving 2 g/dL or more hemoglobin-level increases from baseline without the need for red blood cell transfusions1 Iptacopan demonstrated a 67% differenc